tetano
Editor, Senior Moderator
Expert Rev Anti Infect Ther
. 2021 Aug 4.
doi: 10.1080/14787210.2021.1964955. Online ahead of print.
Anti-inflammatory Effects of GLP-1 in Patients with COVID-19
Saharnaz Sazgarnejad[SUP] 1 2 3 [/SUP], Niloufar Yazdanpanah[SUP] 1 3 4 [/SUP], Nima Rezaei[SUP] 3 4 5 [/SUP]
Affiliations
Abstract
Understanding the pathogenesis and risk factors to control the coronavirus disease 2019 (COVID-19) is necessary. Due to the importance of the inflammatory pathways in the pathogenesis of COVID-19 patients, evaluating the effects of anti-inflammatory medications is important. Glucagon-like peptide 1 receptor agonist (GLP-1RA) is a well-known glucose-lowering agent with anti-inflammatory effects.Areas covered:Resources were extracted from the PubMed database, using keywords such as glucagon-like peptide-1, GLP-1RA, SARS-CoV-2, COVID-19, inflammation, in April 2021. In this review, the effects of GLP-1RA in reducing inflammation and modifying risk factors of COVID-19 severe complications is discussed. However, GLP-1 is degraded by DPP-4 with a plasma half-life of about 2-5 minutes, which makes it difficult to measure GLP-1 plasma level in clinical settings.Expert opinion:Since no definitive treatment is available for COVID-19 so far, determining promising targets to design and/or repurpose effective medications is necessary.
Keywords: COVID-19; GLP-1; anti-inflammatory; glucagon-like peptide 1 receptor agonists; pro-inflammatory.
. 2021 Aug 4.
doi: 10.1080/14787210.2021.1964955. Online ahead of print.
Anti-inflammatory Effects of GLP-1 in Patients with COVID-19
Saharnaz Sazgarnejad[SUP] 1 2 3 [/SUP], Niloufar Yazdanpanah[SUP] 1 3 4 [/SUP], Nima Rezaei[SUP] 3 4 5 [/SUP]
Affiliations
- PMID: 34348067
- DOI: 10.1080/14787210.2021.1964955
Abstract
Understanding the pathogenesis and risk factors to control the coronavirus disease 2019 (COVID-19) is necessary. Due to the importance of the inflammatory pathways in the pathogenesis of COVID-19 patients, evaluating the effects of anti-inflammatory medications is important. Glucagon-like peptide 1 receptor agonist (GLP-1RA) is a well-known glucose-lowering agent with anti-inflammatory effects.Areas covered:Resources were extracted from the PubMed database, using keywords such as glucagon-like peptide-1, GLP-1RA, SARS-CoV-2, COVID-19, inflammation, in April 2021. In this review, the effects of GLP-1RA in reducing inflammation and modifying risk factors of COVID-19 severe complications is discussed. However, GLP-1 is degraded by DPP-4 with a plasma half-life of about 2-5 minutes, which makes it difficult to measure GLP-1 plasma level in clinical settings.Expert opinion:Since no definitive treatment is available for COVID-19 so far, determining promising targets to design and/or repurpose effective medications is necessary.
Keywords: COVID-19; GLP-1; anti-inflammatory; glucagon-like peptide 1 receptor agonists; pro-inflammatory.